Top

International Journal of Clinical Oncology

Published in:

01-02-2018 | Original Article

Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma

Authors: Yavuz Emre Şükür, Salih Taşkın, Bulut Varlı, Can Ateş, Mete Güngör, Fırat Ortaç

Published in: International Journal of Clinical Oncology | Issue 1/2018

Abstract

Background

Uterine carcinosarcoma (UCS) is a relatively rare and very aggressive tumor. The predictors of survival for patients with UCS have not been determined clearly yet. The aim of the present study was to investigate the possible predictors of disease-free survival (DFS) and overall survival (OS) for patients with UCS.

Methods and materials

All patients with UCS who were treated surgically at a university-based Gynecology Oncology Clinic between January 2008 and December 2014 were recruited into this retrospective cohort study. Data regarding clinical, pathologic and treatment information were obtained retrospectively from hospital records. The Kaplan–Meier method was used to calculate DFS and OS, and Cox regression analysis was performed to define the effects of risk factors on survival.

Results

A total of 88 UCS patients with a median age of 64.5 years were included in the study. Forty-seven (53.4%) patients were diagnosed with stage III disease and seven (7.9%) with stage IV disease. The median follow-up time was 16 months. Among all patients, 60 (68.1%) underwent lymphadenectomy. Optimal cytoreductive surgery was achieved in 67 (76.1%) patients. Stepwise variable selection Cox regression analysis showed that lymph node metastasis was associated with poor DFS (hazard ratio 6.524; 95% CI 2.625–16.211; P < 0.001) and OS (hazard ratio 6.993; 95% CI 2.631–18.587; P < 0.001). Subgroup analysis in both early and advanced-stage diseases revealed no significant impact of risk factors on survival.

Conclusions

Lymph node metastasis is the most significant prognostic factor associated with poor DFS and OS in UCS patients.

Cantrell LA, Blank SV, Duska LR (2015) Uterine carcinosarcoma: a review of the literature. Gynecol Oncol 137:581–588CrossRefPubMed

Jonson AL, Bliss RL, Truskinovsky A et al (2006) Clinical features and outcomes of uterine and ovarian carcinosarcoma. Gynecol Oncol 100:561–564CrossRefPubMed

Bansal N, Herzog TJ, Seshan VE et al (2008) Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behaviour. Obstet Gynecol 112:64–70CrossRefPubMed

Temkin SM, Hellmann M, Lee YC et al (2007) Early-stage carcinosarcoma of the uterus: the significance of lymph node count. Int J Gynecol Cancer 17:215–219CrossRefPubMed

Hoellen F, Waldmann A, Benthin S et al (2014) The role of lympadenectomy in uterine sarcoma: a clinical practical approach based on retrospective analysis. Anticancer Res 34:985–993PubMed

Nemani D, Mitra N, Guo M et al (2008) Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 111:82–88CrossRefPubMed

Sorbe B, Paulsson G, Andersson S et al (2013) A population-based series of uterine carcinosarcomas with long-term follow-up. Acta Oncol 52:759–766CrossRefPubMed

Alagkiozidis I, Grossman A, Tang NZ et al (2015) Survival impact of cytoreduction to microscoic disease for advanced stage cancer of the uterine corpus: a retrospective cohort study. Int J Surg 4:61–66CrossRef

Tanner EJ, Leitao MM Jr, Garg K et al (2011) The role of cytoreductive surgery for newly diagnosed advanced stage uterine carcinosarcoma. Gynecol Oncol 123:548–552CrossRefPubMed

10.

Harano K, Hirakawa A, Yunokawa M et al (2016) Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. Gynecol Oncol 141:447–453CrossRefPubMed

11.

Harano K, Hirakawa A, Yunokawa M et al (2016) Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. Int J Clin Oncol 21:168–176CrossRefPubMed

12.

Thomas MB, Mariani A (2007) Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol 107:190–193CrossRefPubMed

13.

Major FJ, Blessing JA, Silverberg SG et al (1993) Prognostic factors in early‐stage uterine sarcoma: a Gynecologic Oncology Group Study. Cancer 71:1702–1709CrossRefPubMed

14.

Bodner-Adler B, Bodner K, Obermair A et al (2001) Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study. Anticancer Res 21:3069–3074PubMed

15.

Galaal K, Kew FM, Tam KF et al (2009) Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. Eur J Obstet Gynecol Reprod Biol 143:88–92CrossRefPubMed

16.

Park JY, Kim DY, Kim JH et al (2010) The role of pelvic and/or para-aortic lymphadenectomy in surgical management of apparently early carcinosarcoa of uterus. Ann Surg Oncol 17:861–868CrossRefPubMed

17.

Matsuo K, Omatsu K, Ross MS et al (2017) Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecol Oncol 145:78–87CrossRefPubMed

18.

Powell MA, Filiaci PG, Rose PG et al (2010) Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. J Clin Oncol 28:2727–2731CrossRefPubMedPubMedCentral

19.

Otsuki A, Watanabe Y, Nomura H et al (2015) Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit. Int J Gynecol Cancer 25:92–97CrossRefPubMed

20.

Takano T, Otsuki T, Tokunaga H et al (2014) Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study. Int J Clin Oncol 19:1052–1058CrossRefPubMed

21.

Callister M, Ramondetta LM, Jhingran A et al (2004) Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 58:786–796CrossRefPubMed

22.

Wolfson AH, Brady MF, Rocereto T et al (2007) A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 107:177–185CrossRefPubMedPubMedCentral

23.

Reed NS, Mangioni C, Malmström H et al (2008) Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: a European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44:808–818CrossRefPubMed

24.

Zwahlen DR, Schick U, Bolukbasi Y et al (2016) Outcome and predictive factors in uterine carcinosarcoma using postoperative radiotherapy: a RARE Cancer Network Study. Rare Tumors 8:6052CrossRefPubMedPubMedCentral

Title: Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma
Authors: Yavuz Emre Şükür
Salih Taşkın
Bulut Varlı
Can Ateş
Mete Güngör
Fırat Ortaç
Publication date: 01-02-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 1/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1181-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and materials

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance

A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy

Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases

Significance of multiple preoperative laboratory abnormalities as prognostic indicators in patients with urothelial carcinoma of the upper urinary tract following radical nephroureterectomy

Management of hereditary breast and ovarian cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer